Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €33.07 EUR
Change Today +0.26 / 0.79%
Volume 0.0
RHO6 On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
SIX Swiss Ex
Xetra
Mexico
Frankfurt
As of 3:24 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

roche holdings ltd-spons adr (RHO6) Snapshot

Open
€32.62
Previous Close
€32.81
Day High
€33.07
Day Low
€32.62
52 Week High
06/1/15 - €34.25
52 Week Low
10/16/14 - €26.19
Market Cap
227.9B
Average Volume 10 Days
59.5
EPS TTM
--
Shares Outstanding
5.6B
EX-Date
03/4/15
P/E TM
--
Dividend
€0.99
Dividend Yield
2.74%
Current Stock Chart for ROCHE HOLDINGS LTD-SPONS ADR (RHO6)

roche holdings ltd-spons adr (RHO6) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holdings ltd-spons adr (RHO6) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holdings ltd-spons adr (RHO6) Key Developments

F. Hoffmann-La Roche Ltd Announces Availability of New HTLV-I/II Infection Diagnostic Assay

F. Hoffmann-La Roche Ltd. has announced the market availability of the Elecsys HTLV-I/II immunoassay, a diagnostic test to help detect antibodies against Human T-lymphotropic virus I or II infection in donated blood and routine diagnostic samples. The test minimizes the likelihood of missing early or chronic HTLV infections, therefore, reducing the risk of transmission. Its high specificity facilitates a clear and consistent interpretation of results at all disease stages with a minimal need for re-testing, providing maximum efficiency gains for the laboratory and patient safety. Moreover, the efficient test procedure enables healthcare professionals to run a single test within 18 minutes, ensuring the safe and timely supply of blood products.

Roche Holding AG Reports Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Roche Holding AG reported consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported net income of CHF 5.25 billion ($5.5 billion) down 7% from CHF 5.64 billion a year earlier. Revenue rose 3% to CHF 23.59 billion from CHF 22.97 billion a year ago. The significant negative currency impact was a factor in the drop in profit, along with factors such as the impact of recent acquisitions including that of InterMune. Core operating profit decreased 2% to CHF 9.24 billion. Net debt is going up from CHF 14 billion, year-end 2014 to CHF 17.3 billion at half year 2015, which is not surprising that its usual development as it has paid a dividend of CHF 6.9 billion. Profit before taxes was CHF 7,080 million. Net income attributable to the company was CHF 5,154 million or CHF 5.98 per diluted share. Total cash flows from operating activities were CHF 6,567 million against CHF 7,595 million a year ago. Purchase of property, plant and equipment was CHF 1,614 million against CHF 1,271 million a year ago. Purchase of intangible assets was CHF 334 million against CHF 123 million a year ago. The company forecasts 2015 sales to grow low- to mid-single digit at constant exchange rates and core earnings per share to rise ahead of sales at constant exchange rates.

Roche Holding AG Announces Data from Phase II Urothelial Bladder Cancer Study

Roche Holding AG has announced data from the Phase II IMvigor 210 study, which demonstrated that the investigational cancer immunotherapy, atezolizumab, shrank tumors in people with locally advanced or metastatic urothelial bladder cancer, or UBC, who had progressed on initial treatment. Therapy Designation for atezolizumab in people whose metastatic bladder cancer expressed PD-L1. This designation is designed to expedite the development and review of medicines intended to treat serious diseases. IMvigor 210 is an open-label, multicenter, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic UBC, regardless of PD-L1 expression. People in the study were enrolled into one of two cohorts. Cohort 1 consisted of people who had received no prior therapies for locally advanced or metastatic UBC, but who were ineligible for first-line cisplatin-based therapy; results from this cohort are not yet mature. Cohort 2, for which results were announced today, included people whose disease progressed during or following previous treatment with a platinum-based chemotherapy regimen (second-line or later). People received a 1200-milligram intravenous dose of atezolizumab on day one of 21-day cycles until progressive disease (Cohort 1) or loss of clinical benefit (Cohort 2). The primary endpoint of the study was ORR. Secondary endpoints included duration of response (DoR), overall survival (OS), progression-free survival (PFS) and safety. PD-L1 expression was assessed using an investigational immunohistochemistry (IHC) test being developed by Roche Diagnostics. In addition to the IMvigor 210 study, Roche has an ongoing randomised Phase III study, IMvigor 211, comparing atezolizumab with standard-of-care chemotherapy in people who have relapsed UBC, and a planned Phase III study, IMvigor 010, that will evaluate atezolizumab compared with observation in people with early-stage muscle-invasive bladder cancer who are selected for PD-L1 expression and are at risk for recurrence (adjuvant). All studies include the evaluation of a companion test developed by Roche Diagnostics to determine PD-L1 status.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO6:GR €33.07 EUR +0.26

RHO6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $328.87 USD -9.12
Amgen Inc $171.69 USD +0.22
Bayer AG €133.55 EUR -0.325
Gilead Sciences Inc $117.90 USD +2.19
Johnson & Johnson $99.84 USD +0.11
View Industry Companies
 

Industry Analysis

RHO6

Industry Average

Valuation RHO6 Industry Range
Price/Earnings 26.0x
Price/Sales 4.6x
Price/Book 13.4x
Price/Cash Flow 21.2x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.